STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.
Story detail
Read the key details here, then continue on the original publisher.
The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.
Join our channel to receive the latest headlines and breaking stories as soon as they are published.
Comments (0)
Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.
No comments yet. Be the first to share your thoughts!